Dyne Therapeutics said it will present five talks and posters spanning Duchenne muscular dystrophy, myotonic dystrophy type 1 and Pompe disease at the 2026 Muscular Dystrophy Association $(MDA)$ Clinical & Scientific Conference, scheduled for March 8-11, 2026, in Orlando, Florida, and virtually. The company did not indicate this was a change to previously issued information. Event-related materials are expected to be posted in Dyne’s Scientific Publications & Presentations webpage on March 8 at 6:00 p.m. ET, with slides available at the start of each presentation: https://www.globenewswire.com/Tracker?data=sk5TdLI1rgf4T93U4LTc4oksOsf5-lJ6o9x8A_xArvjT7Y9sc11T_BR4hPDP5wXtY7ljcjq1d6y7_HS6GtSJiqBTMXVy0dsHyyZtybmK8DJ83HvhupiKlYfEWY0EulJjgP0zcQmH5ubN0VfB1_SrWSQ2f1isAVoUudeA5ui57XpdOxXDc7nbH1JpxlyzGzkN and https://www.globenewswire.com/Tracker?data=wZP7yNrUBlLxwzSQJP6rUM4o_dQ3-4NSGfLy7_RhQRrS262ZS_xdSe57m4jqVuVooQssg6AUW3_4nOpE5qy7ElMBJqFgRztpE4lBJs2ljRYNTBXj9hvofwxdqdzjVfQYvAosRWTDqh_7zMXKBbX23RegrXiIBEqSLmlSJCrXNu0=. A link to previously presented related results is also provided: https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-additional-one-year-clinical-data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602221600PRIMZONEFULLFEED9658891) on February 22, 2026, and is solely responsible for the information contained therein.